Vitamin Shoppe’s share price hit an all-time high of $64.43 in February 2013, but has lost more than 90% of its value since then. The company’s stock price closed at $3.51 on Friday, which followed a 30% drop in the price in the minutes after the earnings report was released on Wednesday. The accounting step contributed to a $3.72 per-share loss that exceeds the price of each share. The New Jersey-based retailer reported a $106 million goodwill write down in its latest earnings release.
China: Probiotic supplements in e-commerce.Digestion and immunity probiotic supplements in e-commerce.Explained: The US e-commerce probiotic supplements market.Probiotic supplements: Global e-commerce 2018-2020, forecast for 2021.The gut-brain axis: Psychobiotic opportunity in 25 countries.Teleflex completes $170M Standard Bariatrics acquisition.Johnson & Johnson Vision launches overnight, intraocular lenses.7 innovative digital health offerings to treat diabetes.Olympus launches Thunderbeat surgical energy devices.This robotic capsule could deliver large-protein drugs like insulin.FDA clears Nexpowder endoscopic hemostasis system from Medtronic.How Medtronic designed the next generation of GI bleeding treatment.Align Technology launches AI-powered home monitoring for Invisalign clear teeth aligners.
Take the writedown update#
Analysts high on AtriCure following Converge AFib procedure update.
Take the writedown software#
Take the writedown trial#
Jude halted its Enlightn IV trial of the next generation of its renal denervation technology in December 2013, just a few months after it began.įiled Under: News Well, Wall Street Beat Tagged With: Boston Scientific, Covidien, Hypertension, stjudemedical Jude did say that it expects lower sales for EnligHTN this year "driven by expected overall market declines in the treatment of drug-resistant, uncontrolled hypertension," according to its own most recent quarterly filing. Jude Medical (NYSE: STJ), developed its EnligHTN platform internally and hasn’t announced any writedown of those assets. The 4th major player in the RDN stakes, St. The Vessix deal also carried milestone provisions, in this case worth another $300 million. Covidien said the net charge for scuttling the OneShot program was $22 million during the 1st 6 months of its fiscal 2014 year.įor Boston Scientific (NYSE: BSX), which paid $130 million for Vessix and its RDN system in 2012, the decision to delay its RDN program indefinitely resulted in a pre-tax impairment charge of $55 million during the 1st quarter this year. That resulted in total charges of $35 million, partially offset by the reversal of $26 million in milestones due on the Maya acquisition (Covidien paid $60 million up-front in cash and with another $170 million on the line in milestones). The Symplicity-3 failure pushed Covidien (NYSE: COV), which acquired Maya Medical’s OneShot RDN platform in 2012 in a deal worth up to $230 million, to abandon its OneShot program entirely. Based on the results of the trial, we have suspended enrollment of our renal denervation hypertension trials that are being conducted in the U.S., Japan, and India," Medtronic said.
pivotal trial in renal denervation for treatment-resistant hypertension, Symplicity HTN-3, failed to meet its primary efficacy endpoint. "The Ardian impairment resulted from the company’s January 2014 announcement that the U.S. In its most recent quarterly filing with the SEC, Medtronic said it took a $236 million writedown on the Ardian acquisition, including a $192 million charge for in-process R&D and another $44 million writedown of other Ardian assets. Medtronic also halted enrollment in several other trials of the Symplicity device, which the company acquired for $800 million when it bought Ardian in 2010. The news ultimately prompted Medtronic to suspend further trials of the RDN technique, which uses an ablation catheter to interrupt the sympathetic nervous response that plays a role in high blood pressure. But the trial, more rigorously designed than previous trials with a sham control arm, failed to meet its primary efficacy endpoint. Symplicity-3 was widely expected to be a slam dunk, vaulting Medtronic into 1st place in the U.S. Three of the 4 major players in the renal denervation market took big write-downs on their RDN assets after the surprise failure of Medtronic‘s (NYSE: MDT) Symplicity-3 clinical trial.
0 kommentar(er)
